Resistance to epidermal growth factor receptor-targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in molecular anticancer therapy.
• Monoclonal antibodies and tyrosine kinase inhibitors targeting EGFR show clinical benefits but face acquired resistance.
• EGFR levels do not always predict response to EGFR tyrosine kinase inhibitors, highlighting resistance mechanisms.

Purpose of the Study:

• To describe potential molecular mechanisms causing resistance to EGFR-targeted drugs.
• To explore strategies for circumventing or delaying resistance to EGFR antagonists.
• To enhance antitumor activities through combination therapies.

Main Methods:

• Review of molecular mechanisms of acquired resistance to EGFR antagonists.
• Analysis of signaling pathways downstream of EGFR, including PI3K/Akt and MAPK.
• Discussion of combination strategies involving EGFR inhibitors and other targeted agents.

Main Results:

• Acquired resistance to EGFR antagonists can arise from ligand overproduction, receptor mutations, or activation of downstream/alternative pathways.
• EGFR antagonists impact cell proliferation, survival, apoptosis, angiogenesis, invasion, and metastasis.
• Combination therapies targeting shared downstream mediators may overcome resistance.

Conclusions:

• Understanding resistance mechanisms is crucial for effective EGFR-targeted cancer therapy.
• Combination of EGFR antagonists with inhibitors of pathways like IGF-1R or VEGFR may overcome resistance.
• Targeting multiple signaling pathways simultaneously holds promise for enhanced antitumor efficacy.